Reproducible Safety and Efficacy of Atezolizumab Plus Bevacizumab for HCC in Clinical Practice: Results of the AB-Real Study

Claudia Angela Maria Fulgenzi; Jaekyung Cheon; Antonio D’Alessio; Naoshi Nishida; Celina Ang; Thomas U. Marron; Linda Wu; Anwaar Saeed; Brooke Wietharn; Antonella Cammarota; Tiziana Pressiani; Nicola Personeni; Matthias Pinter; Bernhard Scheiner; Lorenz Balcar; Andrea Napolitano; Yi‐Hsiang Huang; Samuel Phen; Abdul Rafeh Naqash; Caterina Vivaldi; Francesca Salani; Gianluca Masi; Dominik Bettinger; Arndt Vogel; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Peter R. Galle; Masatoshi Kudo; Lorenza Rimassa; Amit Singal; Rohini Sharma; Alessio Cortellini; Vincent E. Gaillard; Hong Jae Chon; David J. Pinato

doi:10.2139/ssrn.4158289

Related publications

Article2022

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D’Alessio, Naoshi Nishida, Celina Ang, Thomas U. Marron, Linda Y. Wu, Anwaar Saeed, Brooke Wietharn, Antonella Cammarota, Tiziana Pressiani, Nicola Personeni, Matthias Pinter, Bernhard Scheiner, Lorenz Balcar, Andrea Napolitano, Yi‐Hsiang Huang, Samuel Phen, Abdul Rafeh Naqash, Caterina Vivaldi, Francesca Salani, Gianluca Masi, Dominik Bettinger, Arndt Vogel, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Peter R. Galle, Masatoshi Kudo, Lorenza Rimassa, Amit G. Singal, Rohini Sharma, Alessio Cortellini, Vincent E. Gaillard, Hong Jae Chon, David J. Pinato

Article2025

Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study

Alba Sparacino, Gabriele Di Maria, Marco Vaccaro, Giuseppe Cabibbo, Calogero Cammà, María Reig, Robin Kate Kelley, Amit G. Singal, Ahmed O. Kaseb, Masatoshi Kudo, Lorenza Rimassa, David J. Pinato, Ciro Celsa, Tiziana Pressiani, Naoshi Nishida, Shadi Chamseddine, Ashwini Arvind, Michael Li, Marta Fortuny, Najib Ben Khaled, Massimo Iavarone, Hidenori Toyoda,

Article2025

Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence

Giulia Francesca Manfredi, Claudia Angela Maria Fulgenzi, Ciro Celsa, Bernardo Stefanini, Antonio D’Alessio, Matthias Pinter, B Scheiner, Nichola Awosika, Leonardo Brunetti, Pasquale Lombardi, Charles Latchford, Pei-Chang Lee, Yi‐Hsiang Huang, Chung‐Yen Lin, Andrea Dalbeni, Arndt Vogel, Peter R. Galle, Masatoshi Kudo, Lorenza Rimassa, Hong Jae Chon, Giuseppe Cabibbo, Fabio Piscaglia, Calogero Cammà,

Letter2023

Atezolizumab Plus Bevacizumab in Advanced HCC: Efficacy in NASH-Specific Etiology

Josep M. Llovet, Mathias Heikenwälder

Gastroenterology

Article2022

Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice

Takaaki Tanaka, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, ,